Welcome to our dedicated page for Jyong Biotech Ltd. news (Ticker: MENS), a resource for investors and traders seeking the latest updates and insights on Jyong Biotech Ltd. stock.
Jyong Biotech Ltd. (Nasdaq: MENS) is a Taiwan-headquartered biotechnology company focused on plant-derived (botanical) new drugs for urinary system diseases. The MENS news page on Stock Titan aggregates company announcements, scientific updates, capital markets disclosures, and partnership developments drawn from its public communications.
News about Jyong Biotech often centers on clinical trial milestones for its botanical drug candidates. The company has reported results from Phase III trials for its lead candidate BOTRESO® in benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), as well as Phase II data for MCS-8 (PCP) in prostate cancer prevention. Releases provide details on study design, patient populations, efficacy endpoints, and safety findings, offering insight into how these investigational therapies are progressing through the development pipeline.
Investors and observers can also follow business and regulatory updates, including Jyong Biotech’s Nasdaq initial public offering, use-of-proceeds plans for funding Phase III and earlier-stage trials, and statements about compliance with SEC disclosure obligations. Additional news items cover participation in international industry events, such as the BIO 2025 International Convention and regional urology congresses, where the company presents clinical data and engages with global pharmaceutical companies.
Another regular theme in MENS news is regional partnership activity. Jyong Biotech has announced non-binding letters of intent and memoranda of understanding with pharmaceutical companies in markets such as South Korea and Vietnam to evaluate in-licensing, development, and commercialization of its plant-derived MCS products. These stories help readers understand how the company is pursuing co-commercialization and licensing strategies across the U.S., EU, and Asian markets.
By reviewing the MENS news feed, users can track how Jyong Biotech’s investigational botanical drugs advance, how its collaborations evolve, and how management communicates about market conditions, share price movements, and regulatory matters.
Jyong Biotech (Nasdaq: MENS) reported completion of a Phase II trial for lead candidate MCS-8, showing a 27.3% reduction in prostate cancer incidence and a 17.1% reduction in high-grade disease versus placebo.
Phase II also showed favorable lipid changes (HDL, LDL, triglycerides) with statistical significance, a clean two-year safety signal including stable LDH, and non-binding commercial agreements in South Korea and Vietnam as the company evaluates Asian market entry.
Jyong Biotech (Nasdaq: MENS) reported updated Phase II clinical biomarker analyses for MCS-8 (PCP) in Taiwan showing multiple potentially material findings after two years of treatment. Key outcomes: total cholesterol fell significantly (P=0.036), placebo LDH rose (P=0.024) while MCS-8 did not, and prior efficacy showed 27.3% reduction in overall prostate cancer incidence versus placebo.
The company highlights favorable safety and tolerability over two years and is evaluating expanded indications into lipid management, atherosclerosis, and cardiovascular disease to broaden commercial potential.
Jyong Biotech (Nasdaq: MENS) noted increased share price fluctuation and trading volume on Nasdaq following the lock-up expiry in December 2025. The company said it is in compliance with SEC continuous disclosure rules and is not aware of any material, unpublished price-sensitive information explaining the activity.
Jyong Biotech confirmed ongoing talks with certain investment funds about potential share purchases, reported completed clinical work for API-1 (four Phase III trials in the United States and Taiwan and one Phase II in Taiwan), holds global multi-country invention patents across the Americas, Asia, and Europe, and has signed LOIs with several international pharmaceutical companies while planning further botanical drug development.
Jyong Biotech (Nasdaq: MENS) announced a non-binding Memorandum of Understanding dated December 4, 2025 with a Vietnam pharmaceutical distributor headquartered in Ho Chi Minh City to evaluate development and commercialization of MCS-2 in Vietnam.
The MOU calls for due diligence and discussions on commercial strategy, regulatory pathway and local execution; it is non-binding and may not result in a definitive agreement. The company said MCS-2 remains an investigational new drug candidate not approved in any jurisdiction. The MOU follows a November 24, 2025 non-binding Letter of Intent with a South Korean pharmaceutical company to explore in-licensing and development of plant-derived MCS products.
Jyong Biotech (Nasdaq: MENS) announced a non-binding letter of intent (LOI) with a South Korean pharmaceutical company to evaluate in-licensing and development of its plant-derived investigational drug MCS-2 for the Korean market.
The prospective partner supplies general hospitals and clinics; the LOI is non-exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and closing conditions. The collaboration would pursue co-commercialization using the partner’s local sales network to accelerate market access if definitive terms are agreed. MCS-2 remains an investigational candidate and is not approved in any jurisdiction. Jyong Biotech said it will provide material updates as developments occur.
Jyong Biotech (Nasdaq: MENS) announced completion of the primary endpoint statistical analysis from its Phase II randomized, placebo-controlled trial of plant-derived drug MCS-8 (PCP) in Taiwan on Nov 20, 2025. The study enrolled >700 high-risk subjects across 20 hospitals with two years of treatment.
Key results vs placebo: 27.3% reduction in prostate cancer incidence and 17.1% reduction in high-grade prostate cancer (Gleason ≥7). Safety: two-year dosing showed no increase in adverse-event rates, no drug-related serious adverse events, and no negative effects on liver/kidney function or blood pressure. Lipids improved in the MCS-8 arm (LDL down, HDL up).
MCS-8 remains investigational and the company plans to pursue a multinational Phase III.
Jyong Biotech (NASDAQ:MENS) has received the Innovation Gold Award at the 2025 Taipei Biotech Awards for its oral plant-derived drug BOTRESO®, designed to treat benign prostatic hyperplasia (BPH) and lower urinary tract syndrome (LUTS). The award includes a $26,000 cash prize.
BOTRESO®, developed by subsidiary Health Ever Bio-Tech Co., holds multiple worldwide patents and has completed four Phase III clinical trials in the US and Taiwan. The drug represents the first Taiwan-developed oral botanical drug to receive FDA IND approval and advance to Phase III trials. The company has submitted a New Drug Application (NDA) to the U.S. FDA.
Jyong Biotech (Nasdaq: MENS), a Taiwan-based biotechnology company focused on plant-derived drugs for urinary system diseases, announced its Chairwoman and CEO Fu Feng Kuo will speak at The 2025 Global Business Forum on September 19, 2025.
The event, held at the Taipei International Convention Center, is organized by the Taiwanese Chambers of Commerce of North America in partnership with U.S. venture capital and biotech industry representatives. The forum will focus on three key themes: innovative drug technology development, cross-border clinical collaboration, and strategic capital deployment.
Jyong Biotech (NASDAQ:MENS) has announced the completion of patient enrollment in its Phase II clinical trial for MCS-8, a plant-derived investigational drug candidate for prostate cancer prevention. The trial has successfully enrolled over 700 high-risk subjects across 20 hospitals in Taiwan, involving more than 130 urologists.
The study is designed as a randomized, placebo-controlled trial. Despite COVID-19 challenges, the company has achieved this milestone ahead of schedule. The company plans to analyze the trial data after completing the treatment period and will disclose results according to applicable requirements.
Jyong Biotech (NASDAQ:MENS) presented clinical trial results at the 22nd Urological Association of Asia Congress for two key drug candidates. The company's Phase III trials for BOTRESO®, targeting benign prostatic hyperplasia (BPH), showed significant improvement in lower urinary tract symptoms for Asian and pooled Taiwan-U.S. populations, though U.S. subgroup results were not significant. The 52-week extension studies demonstrated consistent long-term improvement with no serious adverse events.
Additionally, their Phase II trial for MCS-8 (PCP) met primary efficacy endpoints, showing lower rates of positive prostate biopsies and high-grade prostate cancer compared to placebo after 104 weeks. The global BPH market is projected to reach $9.8 billion by 2026, up from $4.1 billion in 2020. Jyong Biotech maintains global patent coverage and is pursuing international partnerships for market entry.
FAQ
What is the current stock price of Jyong Biotech Ltd. (MENS)?
What is the market cap of Jyong Biotech Ltd. (MENS)?
